Clinical Trial Imaging, AI & the Next Wave of Healthcare M&A
Clinical Trial Imaging, AI & the Next Wave of Healthcare M&A
London, UK – Nov 22, 2025 – Image Analysis Group (IAG), is pleased to announce that their CEO Dr. Olga Kubassova, will speak at the Goodwin & EY Healthcare Symposium held during the Jefferies Healthcare Conference in London.
Dr. Kubassova will participate in Session 2 (10:05–10:50 a.m.), titled “The next wave of healthcare M&A: Current healthcare M&A trends, alternative strategies and deal structures, and the increasing role of AI and technology.”
She will join a distinguished panel of leaders from across the healthcare mergers and acquisitions landscape, including representatives from EY-Parthenon, Gallop Oncology, PureTech Ventures, EQT Group, AstraZeneca and MTIP.
The discussion will explore how innovation in data, advanced imaging, artificial intelligence and technology‑enabled business models is reshaping healthcare and bio-pharma transactions and long‑term value creation.
Market Analysis and M&A
Recent analyses show the global clinical trial imaging market growing at around 7–8% annually, with revenues projected to approach or exceed USD 2 billion by the end of this decade, driven by demand for high‑quality imaging endpoints, AI‑enabled readouts and complex oncology/immunology trials.
At the same time, investors and strategics are pursuing aggressive consolidation: clinical trial imaging and diagnostics platforms are frequent M&A targets, and leading players are buying complementary AI, cloud and workflow assets to strengthen their data pipelines and real‑world imaging evidence capabilities.
In this environment, imaging is no longer just a cost centre sitting inside a trial budget—it is a core value driver in transactions. Deal teams are looking closely at how well a target can standardise, curate and analyse imaging data at scale, because this underpins differentiated IP (algorithms, radiomic signatures, imaging‑RWE datasets), defensible margins and multi‑year data monetisation opportunities. Assets that combine robust imaging operations with AI‑driven analytics and clean governance around de‑identified image data are commanding strategic premiums, while those with fragmented or low‑quality imaging infrastructure are at increasing risk of discount or pass.
About Image Analysis Group
At Image Analysis Group, the team is built around one core objective: creating measurable value from imaging and data so that clinical‑stage assets are de‑risked, not just “documented.” Drawing on deep experience in oncology, rheumatology, obesity and immunology, IAG designs imaging strategies that make mechanisms of action visible, quantify organ‑level benefit and risk, and generate the kind of high‑quality evidence that underpins stronger valuations, smarter licensing decisions and more attractive M&A profiles.
By standardising global imaging workflows, applying advanced analytics on DYNAMIKA, and linking imaging readouts to exposure–response, safety and durability, the team helps sponsors answer the questions that most often stall or discount late‑stage assets: does the drug do what the biology promised, in the right patients, at an acceptable risk? In doing so, IAG does not just run images through a core lab; it turns imaging into a strategic asset that supports earlier go/no‑go calls, clearer differentiation versus competitors, and a more compelling data package for investors, partners and acquirers.
IMAGE ANALYSIS GROUP is honoured to contribute its perspective on how imaging and AI can de‑risk development and underpin the next generation of healthcare M&A.
About
Image Analysis Group (IAG) is a trusted partner to life sciences companies, combining deep expertise in medical imaging with the innovative power of its proprietary platform, DYNAMIKA™, to de-risk clinical development and accelerate the delivery of lifesaving therapies to patients. The IAG team designs and executes the imaging part of clinical trials that rely on radiological endpoints to demonstrate the safety and efficacy of new drug candidates. By using AI-powered endpoints and automating data management processes, with IAG you accelerate start-up and database lock, gain real-time visibility on trial progress, ensure clean data for regulatory submissions, and maximize patient recruitment speed. For nearly 20 years, the IAG team has helped reduce investment risk and accelerate study outcomes in over 700 trials, empowering biotech and pharmaceutical sponsors to make data-driven decisions with confidence.
